Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT03165890 |
Date of registration:
|
23/05/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude
|
Scientific title:
|
Effect of Acetazolamide on Visuomotor Learning Performance in Patients With Chronic Obstructive Pulmonary Disease at Altitude |
Date of first enrolment:
|
May 24, 2017 |
Target sample size:
|
78 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03165890 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 4
|
|
Countries of recruitment
|
Kyrgyzstan
| | | | | | | |
Contacts
|
Name:
|
Konrad E Bloch, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University of Zurich |
|
Name:
|
Talant M Sooronbaev, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Male and female patients, age 18-75 yrs.
- COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.
- Born, raised and currently living at low altitude (<800m).
- Written informed consent.
Exclusion Criteria:
- COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC <0.7,
FEV1 <40% predicted, oxygen saturation on room air <92% at 750 m).
- Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic
arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in
the last 2 months.
- Internal, neurologic, rheumatologic or psychiatric disease including current heavy
smoking (>20 cigarettes per day)
- Known renal failure or allergy to acetazolamide and other sulfonamides
Age minimum:
18 Years
Age maximum:
75 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Chronic Obstructive Pulmonary Disease (COPD)
|
Intervention(s)
|
Drug: ACETAZOLAMIDE oral capsule
|
Drug: Placebo oral capsule
|
Primary Outcome(s)
|
visuomotor learning performance, altitude effect
[Time Frame: Day 1 and 2 at 760 m and at 3200m]
|
visuomotor learning performance, drug effect
[Time Frame: Day 2 at 760m and 3200m]
|
Secondary Outcome(s)
|
arterial oxygen saturation
[Time Frame: Day 1 and 2 at 760 m and at 3200m]
|
Secondary ID(s)
|
2017-00137A
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|